tbuckley/cabot-search huggingface dataset:
Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC)
Authors: R. Govindarajan, E. Siegel, I. Makhoul, S. Williamson
Journal: Journal of Clinical Oncology (2009)

e15557 Background: New treatment options are needed for patients with inoperable and metastatic HCC. Sorafenib, a RAF kinase inhibitor, prolongs the time to progression and overall survival compared to best supportive care (5.5 and 10.7 months respectively). Angiogenesis plays important role in the development and progression of HCC. Erlotinib, an EGFR tyrosine kinase inhibitor that down-regulates expression of Vascular Endothelial Growth Factor (VEGF), and bevacizumab, a monoclonal anti-VEGF antibody, have synergistic activity in arresting angiogenesis. The objective of the study was designed to evaluate the efficacy of the combination of bevacizumab and erlotinib. The pre-determined endpoint for a positive result is a 27 week PFS of &gt; 20%. Methods: A phase II study was conducted for newly diagnosed unresectable or metastatic HCC, Child-Pugh class A or B cirrhosis with bilirubin &lt;2.0 mg/dL, transaminases &lt; 5 x ULN, Platelet count &gt;75,000 K/UL and ECOG PS 0–2 who had no prior systemic therapy and were not candidates for liver transplantation. Erlotinib was administered continuously at a daily dose of 150 mg, and bevacizumab was administered at a dose of 15 mg/kg intravenously every three weeks. Subjects were evaluated for disease progression by RECIST criteria. Results: At the time of analysis, 21 subjects were enrolled (16 Child- Pugh class A, 5 class B). 16 were evaluable. The median age was 60 Yrs.(range 33–81). Four subjects (27%) were progression-free at 27 weeks of enrollment (95% CI 8%- 55%). Median (quartiles) time to progression was 10.3 (9.0–57.1) weeks. The median (quartiles) overall survival (OS) was 59.7 (range 24.6- 92.6) weeks. Grade-3 events observed were (no.): fatigue (4), dehydration (2), hematemesis (1), diarrhea (1), nausea (1), and dyspnea (1). Grade-4 events (no.) observed were: myocardial infarction (1), atrial fibrillation (1), and ventricular tachycardia (1); pulmonary edema (1). Conclusions: The results met the predetermined study end point of progression free survival at 27 weeks of &gt; 20%. The combination of bevacizumab and erlotinib should be further evauated as treatment option for patients with HCC. [Table: see text]
Brief Communication: Immunotherapy of Cancer: Tumor Suppression and Regression by Cell Walls of Mycobacterium phlei Attached to Oil Droplets2
Authors: Gary R. Gray, Edgar Ribi, Donald Granger, Reno Parker, Ichiro Azuma, Ken-ichi Yamamoto
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Brief Communication: Immunotherapy of Cancer: Tumor Suppression and Regression by Cell Walls of Mycobacterium phlei Attached to Oil Droplets Get access Gary R. Gray, Gary R. Gray Search for other works by this author on: Oxford Academic PubMed Google Scholar Edgar Ribi, Edgar Ribi Search for other works by this author on: Oxford Academic PubMed Google Scholar Donald Granger, Donald Granger Search for other works by this author on: Oxford Academic PubMed Google Scholar Reno Parker, Reno Parker Search for other works by this author on: Oxford Academic PubMed Google Scholar Ichiro Azuma, Ichiro Azuma Search for other works by this author on: Oxford Academic PubMed Google Scholar Ken-ichi Yamamoto Ken-ichi Yamamoto Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 55, Issue 3, September 1975, Pages 727–730, https://doi.org/10.1093/jnci/55.3.727 Published: 01 September 1975 Article history Received: 20 March 1975 Accepted: 17 May 1975 Published: 01 September 1975
Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer.
Authors: S Cascinu, R Labianca, P Alessandroni, M Marcellini, R R Silva, G Pancera, E Testa, G Martignoni, S Barni, L Frontini, A Zaniboni, G Luporini, R Cellerino, G Catalano
Journal: Journal of Clinical Oncology (1997)

PURPOSE A multiinstitutional trial was performed to confirm the clinical activity, in terms of response rate and toxicity (primary objectives) and duration of responses and survival (secondary objectives), of an intensive weekly regimen in advanced gastric cancer. PATIENTS AND METHODS Patients with measurable unresectable and/or metastatic gastric carcinoma received 1-day per week administration of cisplatin (CDDP) 40 mg/m2, fluorouracil (5FU) 500 mg/m2, epi-doxorubicin (epi-ADR) 35 mg/m2, 6S-stereoisomer of leucovorin 250 mg/m2, and glutathione 1.5 g/m2. On the other days, filgrastim was administered by subcutaneous injection at a dose of 5 mg/kg. One cycle of therapy consisted of eight 1-week treatments. Patients who showed a response or stable disease received a further 6 weeks of therapy. RESULTS Of 105 enrolled patients, 11 had locally advanced unresectable disease only; 33 had primary nonresected and metastatic disease; 48 had metastatic disease and primary tumor resected; 10 had locoregional recurrence and metastatic disease; and three had locoregional recurrence only. After one cycle, 18 complete responses (CRs) and 47 partial responses (PRs) were achieved, for an overall response rate of 62% (95% confidence interval [CI], 53% to 71%). Twenty patients had stable disease and 20 progressed on therapy. The median survival duration of all 105 patients was 11 months, with 1- and 2-year survival rates of 42% and 5%, respectively. World Health Organization (WHO) grade III to IV toxicity, in terms of anemia, neutropenia, thrombocytopenia, and mucositis, was experienced by 40 patients (38%). There were no treatment-related deaths. CONCLUSION These data support the results of the pilot study and confirmed the high activity of the regimen, with acceptable toxicity. This schedule deserves evaluation in the adjuvant setting.
Should we treat HER, too?
Authors: D F Hayes
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.3.697 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8622013 Should we treat HER, too? D F HayesxD F HayesSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.3.697 First Page PDF © 1996 by American Society of Clinical Oncology
Fitness and quality of life in endometrial cancer survivors and controls
Authors: K. Basen-Engquist, D. Lenihan, C. Carmack Taylor, K. Lu, H. Perkins, D. Hughes, K. McFalls, K. Shin
Journal: Journal of Clinical Oncology (2007)

19502 Background: It has been suggested that sedentary behavior during cancer treatment or effects of the treatment itself may decrease cardiorespiratory fitness in cancer survivors. However, few studies have tested whether cancer survivors actually have impaired cardiorespiratory fitness compared to similarly aged individuals who have not had cancer. We investigated whether endometrial cancer survivors had poorer fitness than women of similar age and activity level with no cancer history. Methods: The sample included endometrial cancer survivors in a pilot exercise study; all had been diagnosed with Stage I-IIIa disease and were at least 6 months post- treatment. Controls were recruited from a local multi-speciality clinic. Both groups had no contraindications to exercise and were sedentary. Cardiorespiratory fitness was measured by predicted maximal myocardial oxygen carrying capacity (MV02 max) on a submaximal ramped cycle ergometer test. Quality of life was measured using the SF-36 (physical and mental component scores). Results: The study accrued 20 survivors (Mean age=58.6, SD=7.9; Mean BMI=30.5, SD=7.7) and 13 controls (Mean age=55.8, SD=7.6; Mean BMI=30.3, SD=7.0). In t-tests comparing survivors and controls, there were significant differences in predicted MV02 max (p=0.044) and physical aspects of quality of life (p=0.004), but not mental aspects of quality of life. After adjusting for age and BMI using ANCOVA, the p value for predicted MV02 max increased to 0.068, but differences in physical quality of life remained significant (see Table 1 ). Conclusions: Endometrial cancer survivors have diminished quality of life in the physical domain compared to women who have not had cancer; similar results were found for cardiorespiratory fitness, although the effect was attenuated after adjusting for BMI and age. The results suggest endometrial cancer survivors could benefit from exercise interventions to improve fitness and physical functioning. Table 1 : Fitness and quality of life of endometrial cancer survivors and controls. [Table: see text] No significant financial relationships to disclose.
Fatal and non-fatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion
Authors: K Stolarz-Skrzypek, Tatiana Kuznetsova, L Thijs, Tikhonoff, A Olszanecka, S Malyutina, E Casiglia, J Filipovsky, K Kawecka-Jaszcz, Jan A Staessen
Journal: American Journal of Respiratory and Critical Care Medicine (2011)
AIDS-related Kaposi's sarcoma: still a problem, still an opportunity.
Authors: D W Northfelt
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.6.1109 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8201371 AIDS-related Kaposi's sarcoma: still a problem, still an opportunity. D W NorthfeltxD W NorthfeltSearch for articles by this author https://doi.org/10.1200/JCO.1994.12.6.1109 PDF "AIDS-related Kaposi's sarcoma: still a problem, still an opportunity.." Journal of Clinical Oncology, 12(6), pp. 1109–1110© 1994 by American Society of Clinical Oncology
Antiviral Effects of Amino Acid Derivatives With the Fluorene Substituent on Murine Leukemia Viruses
Authors: H Fujita, S Toyoshima
Journal: JNCI Journal of the National Cancer Institute (1983)

Two new amino acid derivatives with the fluorene substituent, when administered ip to female inbred ICR-CD1 mice inoculated with Friend murine leukemia virus, significantly inhibited virus-induced splenomegaly, reduced viable virus titers in spleen and plasma, and significantly prolonged survival time. These compounds also inhibited multiplication of the strains of the Friend and Moloney murine leukemia viruses in a cell culture system. The action of these compounds on murine leukemia virus was presumely different from that of tilorone.
Improvement of survival in VA patients with gall bladder cancer given chemotherapy
Authors: M. Atiq, M. M. Safa, R. S. Komrokji, A. R. Jazieh, A. F. Muhleman, Z. A. Nahleh, J. Pancoast
Journal: Journal of Clinical Oncology (2006)

4132 Background: Gallbladder carcinoma, though rare, has very poor prognosis. Most of patients with gall bladder carcinoma present with either unresectable disease or metastasis. Median survival in gall bladder carcinoma has been documented to be 6 months in SEER data. There is no data available on the outcome of Veterans’ Affair (VA) patients with gall bladder carcinoma. Impact of chemotherapy in adjuvant and metastatic setting is not well-studied. Methods: We used the VA Central Cancer Registry (VACCR) to analyze VA patients with Gall Bladder cancer diagnosed between 1995 and 2005. The reference date for data collection and reporting is January 1, 1995. This site aggregates the data collected by the medical centers’ cancer registries. Data was entered and analyzed using bio-statistical software SPSS. Results: There were a total of 232 patients. Of these, 185 (79.7%) were whites and 37 (15.9%) were blacks. The mean age was 71 years. Pathology was adenocarcinoma in 198 (85.3%), non-specified carcinoma in 29 (12.5%) and small cell carcinoma in 5 (2.2%) cases. Overall median survival was 5.27 months. Surgery was performed in 119 patients (51%). Only 19 (16%) patients received adjuvant chemotherapy. The baseline characteristics were similar between patients who received adjuvant chemotherapy and no adjuvant chemotherapy. Also, the median survival was similar (8.3 months vs. 8.7 months) (P-value 0.37). In patients who did not undergo surgery, the median survival for patients who received chemotherapy was 8.0 months vs 1.7 months for patients who did not receive chemotherapy (p-value 0.013). Eighty-nine (38.5%) patients were diagnosed with stage IV disease. Amongst these patients chemotherapy improved the median survival (2 months vs. 6.97 months; p-value 0.04). In a Cox regression model stage, surgical margins, surgery, chemotherapy were independent predictors of patient survival. Conclusions: Gall bladder carcinoma in VA patients has similar survival compared to other reports. Our data is one of the largest retrospective cohorts in gall bladder cancer and suggests that chemotherapy improves survival in advanced gall bladder cancer patients. No significant financial relationships to disclose.
A rational clinical staging system for childhood rhabdomyosarcoma.
Authors: S S Donaldson, J A Belli
Journal: Journal of Clinical Oncology (1984)

There is a need for a rational and useful staging system for childhood rhabdomyosarcoma that predicts prognosis based on the biology and natural history of the disease. Important factors to consider are age, histology, tumor volume, extent of invasion, and lymphatic involvement. A clinical staging system based on a classical tumor/node/metastasis status, and which accounts for natural history as a function of site of primary, local invasion, and lymphatic or hematogenous metastases is presented. This staging system eliminates the requirement that stage is assigned following an initial therapeutic strategy and removing the implication that prognosis is determined by that strategy.
STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides
Authors: Pablo A. Vieyra-Garcia, Tianling Wei, David Gram Naym, Simon Fredholm, Regina Fink-Puches, Lorenzo Cerroni, Niels Odum, John T. O'Malley, Robert Gniadecki, Peter Wolf
Journal: Clinical Cancer Research (2016)

Sustained inflammation is a key feature of mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL). Resident IL9-producing T cells have been found in skin infections and certain inflammatory skin diseases, but their role in MF is currently unknown.We analyzed lesional skin from patients with MF for the expression of IL9 and its regulators. To determine which cells were producing IL9, high-throughput sequencing was used to identify malignant clones and Vb-specific antibodies were employed to visualize malignant cells in histologic preparations. To explore the mechanism of IL9 secretion, we knocked down STAT3/5 and IRF4 by siRNA transfection in CTCL cell lines receiving psoralen+UVA (PUVA) ± anti-IL9 antibody. To further examine the role of IL9 in tumor development, the EL-4 T-cell lymphoma model was used in C57BL/6 mice.Malignant and reactive T cells produce IL9 in lesional skin. Expression of the Th9 transcription factor IRF4 in malignant cells was heterogeneous, whereas reactive T cells expressed it uniformly. PUVA or UVB phototherapy diminished the frequencies of IL9- and IL9r-positive cells, as well as STAT3/5a and IRF4 expression in lesional skin. IL9 production was regulated by STAT3/5 and silencing of STAT5 or blockade of IL9 with neutralizing antibodies potentiated cell death after PUVA treatment in vitro IL9-depleted mice exhibited a reduction of tumor growth, higher frequencies of regulatory T cells, and activated CD4 and CD8 T lymphocytes.Our results suggest that IL9 and its regulators are promising new targets for therapy development in mycosis fungoides. Clin Cancer Res; 22(13); 3328-39. ©2016 AACR.
Cancer screening tests in France: First results of EDIFICE study
Authors: X. Pivot, D. Serin, Y. Coscas, F. Eisinger, O. Rixe, C. Roussel, J. Morere, J. Blay
Journal: Journal of Clinical Oncology (2006)

6092 Background: The EDIFICE study was the first which aimed to allow better understanding of population’s adhesion in France to the screening tests available for the 4 most frequent cancers: breast, colorectal, prostate and lung. Methods: This nationwide observational study was carried out in France from January 18th to February 2nd, 2005 among a representative sample of 1,504 subjects aged between 40 and 75 years and a representative sample of 600 general practitioners (GPs). Information collected about participating subjects included socio-demographic characteristics, attitude towards cancer screening and actual experience of cancer screening, and about GPs’ medical practice regarding screening. Results: A striking result observed is that screening for colorectal cancer that USPSTF rates as an “A” Recommendation (strongly recommended) deserves less attention: reported rate 25% than prostate cancer screening (either with digital rectal examination and/or PSA): reported rate 36%. In the same way, GPs’ are recommended more often prostate cancer screening (58%) than colorectal cancer screening (18%). Another key result of that EDIFICE national representative survey is the high attendance rate of women at mammography screening. Conclusion: With respect to the cost of such programs, utilization must be monitored and compared among different countries/organization. Additional data will be presented about reasons to do or not cancer screening and about regularity of screening. [Table: see text] No significant financial relationships to disclose.
Cancer patient perspective on an anthology addressing end-of-life care: A qualitative study of <i>The Art of Oncology, When the Tumor is Not the Target</i>
Authors: K. S. Vickers, J. C. Hathaway, C. A. Patten, M. M. Clark, T. L. Britt, S. A. Looker, P. T. Johnson, T. J. Moynihan, C. L. Loprinzi
Journal: Journal of Clinical Oncology (2004)

8208 Background: Because cancer patients and healthcare professionals have been shown to differ in their beliefs about what information is appropriate for cancer patients, it is necessary to obtain patient perspective on new sources of information. The purpose of the study was to identify patient opinion on the emotional impact, clinical impact, and appropriateness of sharing with cancer patients an anthology emphasizing end-of-life care. Methods: In this qualitative research study, 22 patients with advanced-stage cancer and 6 patient advocates received a copy of an anthology entitled, “The Art of Oncology: When the Tumor is Not the Target,” and then completed an individual semi-structured interview assessing the emotional impact and clinical impact (e.g., patient-physician communication) of the anthology. Participants also made recommendations regarding sharing the anthology with other cancer patients. Interview transcripts were coded using methods of content analysis, facilitated through use of N6 qualitative data analysis program. Results: Overall, participants approved of sharing the anthology with select patients, especially those who are active in their care, accepting of their cancer status, and emotionally ready to read about end-of-life issues. For these patients, participants described the anthology as having potential for positive impact on patient-physician communication, patient-physician relationship (e.g., increased empathy for oncologists), patient consideration of treatment options, and patient preparations for end-of-life care. Nonetheless, the anthology was considered “depressing” and “lacking in hope” by several participants. Men were more likely than women to decline interview and/or immediately discontinue reading the anthology after experiencing a strong negative emotional response. Conclusions: This anthology appears to be a valuable resource for some, but certainly not all, patients with advanced-stage cancer. If it is made available for such patients, it is recommended that appropriate warnings, regarding the content, be shared with potential recipients. No significant financial relationships to disclose.
Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.
Authors: M. D. Forster, A. Patnaik, S. K. Sandhu, K. Papadopoulos, B. J. Tromp, C. Messiou, F. Balkwill, B. Berns, J. S. De Bono, A. W. Tolcher
Journal: Journal of Clinical Oncology (2010)

2548 Background: The chemokine CCL2 is highly expressed in various malignancies, and is implicated in tumor angiogenesis, proliferation, and metastasis. CCL2 orchestrates tumor-associated macrophage recruitment and osteoclastic differentiation, fostering tumorigenesis and skeletal metastases. CNTO 888 is a human IgG1κ monoclonal antibody with high CCL2 binding affinity and robust preclinical antitumor activity. Methods: CNTO 888 was administered as a 90-minute infusion on days (d) 1, 29 (for pharmacokinetic [PK] assessment) and q14d thereafter. Pre- and post-therapy pharmacodynamic [PD] evaluation included total and free CCL2 in serum, circulating tumor and endothelial cell enumeration, cytokine profiles, mandated paired tumor biopsies (n=6) for tumor CCL2, CCR2 and macrophage subtypes and exploratory diffusion contrast-enhanced computed tomography (n=6). Results: 44 pts (21M/23F) were treated with CNTO 888: 21 pts in dose-escalation cohorts (0.3, 1, 3, 10, and 15 mg/kg) and 23 pts in 2 dose-expansion cohorts (10 and 15 mg/kg). Reversible grade (G) 3 liver enzymes elevation was seen in 1 pt with progressive liver metastases. No other drug-related G3-4 adverse events (AEs) or dose-limiting toxicity (DLT) was seen. G1-2 AEs included fatigue, nausea, vomiting, pruritus, rash, and headache. PK data showed a dose-proportional increase in mean Cmax and AUC with bi- exponential decline and t1/2 of 4.4-6.9 d. Doses of 10 mg/kg q14d achieved steady-state concentrations required for antitumor activity as defined in preclinical models. Dose-dependent increases in bound CCL2 levels of >1,000-fold were demonstrated. Antitumor activity was observed in 4 pts; CA125 response and RECIST stable disease (SD) for 10 months (m) in ovarian cancer, PSA response and SD for 5m in prostate cancer, 7m SD in ocular melanoma and 15m SD in neuroendocrine tumor. Conclusions: CNTO 888 is well tolerated with no DLT. PKs are dose proportional, with evidence of PD target modulation and antitumor activity. The recommended phase II dose for single-agent CNTO 888 is 15 mg/kg q14d. Phase II studies are ongoing in prostate and planned in ovarian cancer. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Johnson & Johnson, Ortho Biotech Johnson & Johnson Chemotherapy Foundation, Johnson & Johnson Johnson & Johnson